Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

The US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to ...

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight. Dedania ...

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

The course is designed for comprehensive and pediatric ophthalmologists and optometrists, who often see patients with new ...

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

When people ask how I define a successful premium IOL outcome, they usually expect a number. The honest answer is that a ...

A trip to Armenia gives ophthalmologists the chance to teach surgery, watch skilled surgeons, and make a difference where health care is still advancing, according to John A. Hovanesian, MD, of ...

Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.

MOGAD more commonly presents with bilateral optic neuritis and more disc edema at onset, Chen said, with substantial optic ...

A multicenter cohort found that adjunctive topical antibiotic documentation was not associated with a statistically ...